{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:42:29Z","timestamp":1785757349084,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijid.2025.107867","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:08:48Z","timestamp":1741090128000},"page":"107867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Modulation of the renin-angiotensin system against COVID-19: A path forward?"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-8503","authenticated-orcid":false,"given":"Serge","family":"Camelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waly","family":"Dioh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-9644","authenticated-orcid":false,"given":"J. Pedro","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6564-5200","authenticated-orcid":false,"given":"Laurence W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Plantefeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Morelot-Panzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana Margareth","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley H.","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1212-6697","authenticated-orcid":false,"given":"Rob","family":"Van Maanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Veillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.107867_bib0001","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2025.107867_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.123.21364","article-title":"Alternative renin-angiotensin system","author":"Bader","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.ijid.2025.107867_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ijid.2025.107867_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.02.010","article-title":"Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients","author":"Latil","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijid.2025.107867_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2025.107867_bib0006","article-title":"Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial","volume":"379","author":"Jardine","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2025.107867_bib0007","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized prospective open label study shows No impact on clinical outcome of adding Losartan to hospitalized COVID-19 patients with mild hypoxemia","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.107867_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100968","article-title":"COVIDMED - an early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients","volume":"29","author":"Freilich","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ijid.2025.107867_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2735","article-title":"Efficacy of Losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial","volume":"5","author":"Puskarich","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2025.107867_bib0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/cid\/ciae306","article-title":"Effects of Losartan on patients hospitalized for acute COVID-19: a randomized controlled trial","volume":"79","author":"Tran","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.107867_bib0011","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1111\/ijcp.14124","article-title":"Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial","volume":"75","author":"Nouri-Vaskeh","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijid.2025.107867_bib0012","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.2023.4480","article-title":"Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: a randomized clinical trial","volume":"329","author":"Lawler","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2025.107867_bib0013","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1007\/s12325-023-02618-7","article-title":"Ramipril for the treatment of COVID-19: RAMIC, a randomized, double-blind, placebo-controlled clinical trial","volume":"40","author":"Huang","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijid.2025.107867_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin-Angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the international society of hypertension","volume":"11","author":"Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ijid.2025.107867_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101152","article-title":"Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multicenter double-blind phase 2 trial","volume":"41","author":"Tornling","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2025.107867_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13054-022-04096-9","article-title":"A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19","volume":"26","author":"Wagener","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2025.107867_bib0017","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2023.3546","article-title":"Renin-Angiotensin system modulation with synthetic Angiotensin (1-7) and Angiotensin II type 1 receptor-biased ligand in adults with COVID-19: two randomized clinical trials","volume":"329","author":"Self","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2025.107867_bib0018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/JME-21-0033","article-title":"20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor","volume":"68","author":"Lafont","year":"2021","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.ijid.2025.107867_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102383","article-title":"Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2\/3 trial","volume":"68","author":"Lobo","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2025.107867_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3317\/jraas.2002.046","article-title":"The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease","volume":"3","author":"Sica","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.ijid.2025.107867_bib0021","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-005-0078-4","article-title":"Phase I\/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer","volume":"57","author":"Rodgers","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijid.2025.107867_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13195","article-title":"A phase 1 study for safety and pharmacokinetics of BIO101 (20-hydroxyecdysone) in healthy young and older adults","author":"Dioh","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ijid.2025.107867_bib0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13613-024-01369-0","article-title":"Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial","volume":"14","author":"Martins","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijid.2025.107867_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103520","article-title":"Karnik SS. Atypical signaling and functional desensitization response of MAS receptor to peptide ligands","volume":"9","author":"Tirupula","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.107867_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115370","article-title":"Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic","volume":"208","author":"Chen","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijid.2025.107867_bib0026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2023.10783","article-title":"Renin-angiotensin system modulation in adults with COVID-19","volume":"330","author":"Dos Santos","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2025.107867_bib0027","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jama.2023.10786","article-title":"Renin-Angiotensin system modulation in adults with COVID-19-reply","volume":"330","author":"Self","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2025.107867_bib0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2021.09.007","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later","volume":"93","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ijid.2025.107867_bib0029","article-title":"Molecular PET\/CT profiling of ACE2 expression In vivo: implications for infection and outcome from SARS-CoV-2","volume":"8","author":"Zhu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ijid.2025.107867_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijid.2025.107867_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102755","article-title":"Quantifying Renin-Angiotensin-system alterations in COVID-19","volume":"10","author":"Pucci","year":"2021","journal-title":"Cells"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:13:20Z","timestamp":1762366400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S1201971225000906"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107867","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of the renin-angiotensin system against COVID-19: A path forward?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107867"}}